Loading
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Previous close
$35.36
−$1.00 · -2.75%
After-hours
$35.28
−$0.08 · -0.23%
Sep 4, 7:51 PM ET
Regular session · ET · Market data may be delayed.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Day range
Current $35.36
52-week range
Current $35.36
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
28
Expensive
Sentiment
67
Bullish
Risk
58
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Day range
Current $35.36
52-week range
Current $35.36
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 26.71M USD | 25.95M USD | 11M USD | 8.71M USD |
| Gross profit | — | −26.71M USD | −25.95M USD | −11M USD | −8.71M USD |
| Research and development | 182.37M USD | 126.1M USD | 206.3M USD | 267.59M USD | 217.34M USD |
| Selling, general, and administrative | 52.02M USD | 34.05M USD | 71.02M USD | 62.79M USD | 41M USD |
| Operating expenses | 234.39M USD | 160.14M USD | 251.37M USD | 330.38M USD | 258.34M USD |
| Interest income | 4.52M USD | 11.15M USD | 16.73M USD | 7.07M USD | 298K USD |
| Interest expense | — | — | 13K USD | 18K USD | 22K USD |
| Depreciation and amortization | 26.32M USD | 26.71M USD | 25.95M USD | 11M USD | 8.71M USD |
| Operating income | −234.39M USD | −186.85M USD | −277.32M USD | −341.38M USD | −267.05M USD |
| Net income | −229.97M USD | −176.21M USD | −260.49M USD | −333.82M USD | −266.99M USD |
Company facts updated Sep 5, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$63.75
80.29% upsidePrice history unavailable
High $80.00Average $63.75Low $56.00| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 23, 2022 | 5:1 | — | — |
Effective Feb 23, 2022
5:1
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
